PAVmed (PAVM)

Executive Summary

PAVmed is a commercial-stage, diversified medical technology company focused on disruptive innovation in medical devices, diagnostics, and digital health. Its portfolio includes Lucid Diagnostics, which offers the EsoGuard® esophageal precancer test, and Veris Health, a remote patient monitoring platform for cancer care. Leveraging a shared-services model, PAVmed aims to achieve operational efficiency and scale across its subsidiaries. The company's current commercial efforts center on expanding adoption of EsoGuard for Barrett's esophagus screening and advancing Veris Health's remote monitoring solutions. Despite being early in commercialization, PAVmed has secured key reimbursement wins and partnerships that position it for growth. The company's valuation of approximately $51 million and its small market cap reflect its speculative nature, but also its potential upside if its products gain traction. Near-term focus remains on driving revenue from Lucid Diagnostics and Veris Health while exploring strategic opportunities to maximize shareholder value.

Upcoming Catalysts (preview)

• Q3 2026Lucid Diagnostics EsoGuard Reimbursement Expansion and Commercial Uptake70% success
• Q4 2026Veris Health Remote Monitoring Platform Partnership or Commercial Launch60% success
• Q3 2026Potential Capital Raise or Strategic Collaboration to Fund Growth50% success